Patents by Inventor Kallanthottathil G. Rajeev

Kallanthottathil G. Rajeev has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • REVERSIR TM COMPOUNDS
    Publication number: 20220259589
    Abstract: The present invention relates, in general to agents that modulate the pharmacological activity of conjugated siRNAs.
    Type: Application
    Filed: August 10, 2021
    Publication date: August 18, 2022
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Vasant JADHAV, John MARAGANORE, Martin MAIER, Kallanthottathil G. RAJEEV, Muthiah MANOHARAN, Akin AKINC, Ivan ZLATEV
  • Modified RNAi agents
    Patent number: 11406716
    Abstract: One aspect of the present invention relates to double-stranded RNAi (dsRNA) duplex agent capable of inhibiting the expression of a target gene. The dsRNA duplex comprises one or more motifs of three identical modifications on three consecutive nucleotides in one or both strand, particularly at or near the cleavage site of the strand. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: August 9, 2022
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Kallanthottathil G. Rajeev, Tracy Zimmermann, Muthiah Manoharan, Martin Maier, Satyanarayana Kuchimanchi, Klaus Charisse
  • Biodegradable lipids for the delivery of active agents
    Patent number: 11400158
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Grant
    Filed: January 12, 2022
    Date of Patent: August 2, 2022
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • Biodegradable lipids for the delivery of active agents
    Patent number: 11382979
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: July 12, 2022
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • ENDOSOMAL CLEAVABLE LINKERS
    Publication number: 20220177885
    Abstract: The present disclosure relates generally to cleavable linkers and uses thereof.
    Type: Application
    Filed: February 10, 2022
    Publication date: June 9, 2022
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Jayaprakash K. NAIR, Kallanthottathil G. RAJEEV, Scott LENTINI, Christopher S. THEILE, Martin MAIER, Ivan ZLATEV
  • BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS
    Publication number: 20220175928
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Application
    Filed: February 14, 2022
    Publication date: June 9, 2022
    Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS
    Publication number: 20220175930
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Application
    Filed: February 14, 2022
    Publication date: June 9, 2022
    Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS
    Publication number: 20220175929
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Application
    Filed: February 14, 2022
    Publication date: June 9, 2022
    Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY
    Publication number: 20220152210
    Abstract: Provided herein are compositions, methods of making the same, and methods for targeted delivery of therapeutic agents for modifying expression and function of target genes, e.g. proteins involved in lipid and cholesterol metabolism such as PCSK9. Further provided herein are compositions and methods of treating conditions related to coronary disease.
    Type: Application
    Filed: November 23, 2021
    Publication date: May 19, 2022
    Inventors: Kallanthottathil G. Rajeev, Souvik Biswas, Padma Malyala, Lisa N. Kasiewicz, Alexandra Chadwick, Caroline Reiss
  • CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES
    Publication number: 20220143189
    Abstract: The present invention provides a modified RNAi agent comprising a sense strand and an antisense strand, wherein the antisense strand targets an HBV mRNA; all of the nucleotide sugars of the RNAi agent are 2?-modified; and at least one of the sense and antisense strands is conjugated to at least one targeting ligand that comprises two or more building blocks connected to a biantennary or triantennary branched linker, optionally via one or more linking groups.
    Type: Application
    Filed: November 23, 2021
    Publication date: May 12, 2022
    Inventors: Muthiah MANOHARAN, Kallanthottathil G. RAJEEV, Jayaprakash K. NAIR, Martin MAIER
  • BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS
    Publication number: 20220125927
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Application
    Filed: January 12, 2022
    Publication date: April 28, 2022
    Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G Rajeev, Muthiah Manoharan
  • REVERSIR TM COMPOUNDS
    Publication number: 20220127604
    Abstract: The present invention relates, in general to agents that modulate the pharmacological activity of conjugated siRNAs.
    Type: Application
    Filed: August 10, 2021
    Publication date: April 28, 2022
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Vasant JADHAV, John MARAGANORE, Martin MAIER, Kallanthottathil G. RAJEEV, Muthiah MANOHARAN, Akin AKINC, Ivan ZLATEV
  • EXTRAHEPATIC DELIVERY
    Publication number: 20220125823
    Abstract: The invention relates to a method of gene silencing, comprising administering to a cell or a subject in need thereof a therapeutically effective amount of the lipophilic moieties-conjugated double-stranded iRNAs at one or more internal positions on at least one strand, optionally via a linker or carrier.
    Type: Application
    Filed: May 7, 2019
    Publication date: April 28, 2022
    Inventors: Jayaprakash K. NAIR, Martin MAIER, Vasant JADHAV, Stuart MILSTEIN, Kirk BROWN, Rubina G. PARMAR, Kallanthottathil G. RAJEEV, Muthiah MANOHARAN, Alexander V. KEL'IN, Muthusamy JAYARAMAN, Klaus CHARISSE, Adam CASTORENO, Christopher S. THEILE, Kevin FITZGERALD
  • BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS
    Publication number: 20220111053
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Application
    Filed: December 17, 2021
    Publication date: April 14, 2022
    Inventors: MARTIN MAIER, MUTHUSAMY JAYARAMAN, AKIN AKINC, SHIGEO MATSUDA, PACHAMUTHU KANDASAMY, KALLANTHOTTATHIL G. RAJEEV, MUTHIAH MANOHARAN
  • MULTI-TARGETED SINGLE ENTITY CONJUGATES
    Publication number: 20220106593
    Abstract: The present invention relates, in general to, compounds, compositions and methods useful for modulating gene expression of multiple target nucleic acids by a single chemical entity.
    Type: Application
    Filed: February 22, 2021
    Publication date: April 7, 2022
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Vasant JADHAV, Martin MAIER, Ivan ZLATEV, Akin AKINC, Kallanthottathil G. RAJEEV, Jayaprakash K. NAIR, Pachamuthu KANDASAMY, Muthiah MANOHARAN
  • BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS
    Publication number: 20220105187
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Application
    Filed: December 17, 2021
    Publication date: April 7, 2022
    Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • Endosomal cleavable linkers
    Patent number: 11286482
    Abstract: The present disclosure relates generally to cleavable linkers and uses thereof.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: March 29, 2022
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Jayaprakash K. Nair, Kallanthottathil G. Rajeev, Scott Lentini, Christopher S. Theile, Martin Maier, Ivan Zlatev
  • Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
    Patent number: 11286486
    Abstract: The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: March 29, 2022
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Tracy Zimmermann, Amy Chan, Vasant R. Jadhav, Martin A. Maier, Kallanthottathil G. Rajeev
  • COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20220090068
    Abstract: The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.
    Type: Application
    Filed: July 12, 2021
    Publication date: March 24, 2022
    Inventors: Kevin Fitzgerald, James Butler, Brian Bettencourt, Anna Borodovsky, Satyanarayana Kuchimanchi, Klaus Charisse, Muthiah Manoharan, Martin A. Maier, Kallanthottathil G. Rajeev, Donald Foster
  • Biodegradable lipids for the delivery of active agents
    Patent number: 11246933
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Grant
    Filed: April 29, 2021
    Date of Patent: February 15, 2022
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan